Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
FRONTIERS IN NEPHROLOGY
You have accessRestricted Access

Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management

Gunter Wolf and Eberhard Ritz
JASN May 2003, 14 (5) 1396-1405; DOI: https://doi.org/10.1097/01.ASN.0000065639.19190.CF
Gunter Wolf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eberhard Ritz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

It is an irony of medical progress that the renal involvement in diabetes mellitus type 2 had been considered twenty years ago (1) as a benign condition for the kidney without causing renal function loss greater than expected from the “normal” aging process. In contrast, today it has become the single most common cause of end-stage renal disease (ESRD) in the entire Western world (2–4⇓⇓). Apart from the individual human suffering that cannot be expressed in numbers, patients with type 2 diabetes undergoing maintenance dialysis consume significantly more financial resources than those with nondiabetic ESRD. In addition, type 2 diabetic patients do poorly on dialysis and have an excess mortality (5). An interdisciplinary approach is needed for patients with type 2 diabetes and nephrologists must deal with a spectrum of comorbidity besides diabetic nephropathy. The famous Dr. Elliot P. Joslin (1869–1962) stated: “With a missionary zeal, one must convert not only the patient’s mind and soul, but also his doctor to the realization that it is worth the effort to control the disease as shown by the sugar-free urine, normal blood sugar and cholesterol” (6). We posit that a similar approach is also indicated with respect to prevention and treatment of nephropathy in patients with type 2 diabetes mellitus.

Some Factors Involved in the Genesis of Diabetic Nephropathy in Type 2 Diabetes

To understand therapeutic interventions, it is mandatory to briefly provide an (incomplete) review of the salient pathophysiologic mechanisms involved in the genesis of renal disease in diabetes.

Type 2 diabetes is characterized by insulin resistance, i.e., the failure to respond to normal concentrations of insulin, and this is accompanied by compensatory hyperinsulinemia, although the kinetics of insulin secretion are abnormal very early. In later stages, β cell secretion fails to overcome insulin resistance (7). Increased lipolysis with fatty acid release and accumulation of fat in parenchymal organs further aggravate the metabolic disturbance. Insulin resistance is the result of genetic (7) as well as environmental factors. In subgroups of patients with type 2 diabetes, monogenetic causes have been identified, but which genes are responsible for the more common polygenic forms is still unclear (8).

How Do Microvascular Complications, Including Renal Disease, Develop?

Recent evidence suggests that increased superoxide formation after high glucose–induced throughput in the mitochondrial electron-transport chain generates reactive oxygen species, which are involved in the development of diabetic complications (9). Particularly in the development of diabetic nephropathy, proteins modified by glucose or glucose-derived products such as methylglyoxal, i.e., Amadori products, and advanced glycation end products (AGE) play a pivotal role (10). Increased mitochondrial oxydation of glucose also activates protein kinase C (PKC) (9) and subsequently mitogen-activated protein kinases (MAPK) (11). Transforming growth factor-β (TGF-β) appears to be crucial in the development of renal hypertrophy and accumulation of extracellular matrix (12). Renal hypertrophy is an early event; irreversible changes such as glomerulosclerosis and tubulointerstitial fibrosis are preceded by hypertrophy (12). Parallel to and to some extent concomitant with renal hypertrophy, hyperfiltration and intrarenal hypertension develop in type 1 (10) as well as in type 2 diabetes (13). Both hemodynamic and structural changes are important and are interrelated. For example, high glucose stimulates the synthesis of angiotensinogen and angiotensin II (AngII) (14). This polypeptide exerts hemodynamic as well as trophic, inflammatory, and profibrogenic effects on renal cells (15). On the other hand, shear stress and mechanical strain, resulting from altered glomerular hemodynamics and glomerular hypertension, induce the autocrine and/or paracrine release of cytokines and growth factors (14), which in turn plays a role in genesis of glomerulosclerosis and interstitial fibrosis.

The risk of nephropathy is strongly determined by genetic factors. Cardiovascular disease (16) as well as renal disease (17) cluster within families. A positive family history is clinically useful to identify patients with type 2 diabetes at high renal risk. There has been an intense effort to identify the genes coding for renal risk. The complexity of candidate gene analysis is exemplified by controversial results concerning the insertion/deletion polymorphism of the angiotensin-converting enzyme (ACE). The current majority opinion is that, at least in certain ethnic populations, this polymorphism is associated with progression of diabetic renal disease but is not useful to predict development of diabetic nephropathy (18,19⇓). Positional analysis has also identified putative loci associated with higher renal risk, at least in selected populations (20), but the generalizability of the results and the functional role of the hypothetical genes have not yet been clarified.

How to Diagnose Type 2 Diabetes?

Recently, the American Diabetes Association (ADA) recommended diagnosis of type 2 diabetes on the basis of a fasting plasma glucose concentration ≥ 126 mg/dl (7.0 mmol/L) on two different days or a casual plasma glucose concentration ≥ 200 mg/dl (11.1 mmol/L) at any time of the day without regard to time elapsed since the last meal (21). In contrast, the WHO continues to recommend oral glucose tolerance testing. A 2-h value ≥ 200 mg/dl (11.1 mmol/L) is diagnostic of diabetes. The agreement between ADA and WHO criteria is not satisfactory. Many individuals diagnosed with diabetes on the basis of WHO criteria would be missed by ADA criteria (22). The oral glucose tolerance test provides, in addition, prognostic information and identifies individuals with the greatest attributable risk of cardiovascular events and death (22,23⇓). Glucose tolerance is influenced by renal dysfunction and by medication (24). We recommend oral glucose tolerance tests in high-risk populations (Table 1) even when the fasting plasma glucose concentration is normal.

View this table:
  • View inline
  • View popup

Table 1. Risk factors for impaired glucose tolerance or latent type 2 diabetes

Heterogeneity of Renal Involvement in Type 2 Diabetes

Structural damage to the kidney in diabetes mellitus is usually, but not uniformly (25), reflected by microalbuminuria (MA), i.e., elevated urinary albumin excretion (30 to 300 mg/d) in 24-h urine collections or 20 to 200 μg/min or μg/ml in spot urine samples. Some consensus recommendations advise to correct urinary albumin in spot urine for creatinine concentration (albumin/creatinine ratio 2.5 to 25 mg albumin/mmol creatinine) and some to use even separate cutoffs for male and female patients. Because albumin excretion shows high day-to-day variability (VC 30%), MA should be diagnosed only if two of three samples on different days test positive in the absence of confounding factors such as fever, physical exercise, urinary tract infection, uncontrolled hypertension, uncontrolled hyperglycemia, or congestive heart failure. There is a progressive increase of renal (and cardiovascular) risk with increasing albumin excretion rates (26,27⇓). This is true even for urinary albumin concentrations within the upper normal range, so that the cut-off must be interpreted with a grain of salt. Thickening of the glomerular basement membrane causing textural abnormalities and abnormal chemical composition as well as loss of negative electric charges had in the past been thought to be the major cause of MA. More recently, disturbances of the number and function of podocytes and specifically the function of the slit membrane are thought to be at least equally important (28). MA is not only a predictor of future nephropathy (10); it is also associated with increased transcription of genes involved in the genesis of glomerulosclerosis (29), at least in type 1 diabetes. Consequently, MA is evidence of existing nephropathy, not a predictor of future nephropathy. The association between glomerular lesions and MA is less pronounced in type 2 diabetes (25). Fioretto et al. (25) found an overall relation, but some patients failed to have MA despite glomerulosclerosis and conversely approximately 30% of microalbuminuric type 2 diabetic patients had structurally normal glomeruli. The known correlation of MA to cardiovascular events (27) may be explained by the fact that the generalized microvascular and macrovascular complications in type 2 diabetes are also found in the kidney, making MA a mirror of the generalized vascular pathology. There is experimental evidence for a role of AngII in reducing nephrin expression in the slit diaphragm of podocytes (30), thus explaining the BP-independent beneficial effect of angiotensin receptor blockers on MA in type 2 diabetic patients (31). The podocyte appears also to be a key player in the progression of renal disease. Kidney biopsies in Pima Indians with type 2 diabetes and MA showed increased glomerular and mesangial volumes, while subjects with overt proteinuria exhibited broadening of podocyte foot processes and reduced numbers of podocytes (32). Podocyte loss is also found in experimental models of diabetes (33) and in patients with type 1 (34) as well as type 2 diabetes (35) and progressive nephropathy. The dogma of MA as a specific reflection of disturbed glomerular permselectivity has recently come under critique, however, because disturbances of proximal tubular reabsorption of albumin have been shown to be a major component of albuminuria in experimental models (36) and in diabetic patients (37).

Several studies in microalbuminuric patients with type 2 diabetes (25,38⇓) documented that the morphology is much more heterogeneous than in microalbuminuric type 1 diabetic patients. This contrasts with the observations in frankly proteinuric type 2 diabetic patients with impaired renal function in whom one uniformly finds diabetic glomerulosclerosis (39).

It was previously thought (40) that MA is uniformly associated with a decrease in GFR. In contrast, more recent studies (41) showed that this is true mainly for the subgroup of patients exhibiting typical lesions of diabetic glomerulopathy. An Australian group even identified a subgroup of patients with type 2 diabetes and progressive decrease of creatinine clearance despite no increase in albuminuria (42). Unfortunately there is no information on the underlying renal morphology.

In contrast to type 1 diabetic patients in whom marked diabetic glomerulosclerosis is almost uniformly associated with diabetic retinopathy, the latter is found only in approximately 70% of patients according to the IDNT study (43). It is, however, a powerful predictor of an adverse renal prognosis (44).

There have been reports that one often finds “minimal change” lesions in proteinuric type 2 diabetic patients by light microscopy (45), but it is not perfectly clear whether this constellation reflects early diabetes-related podocyte damage that escapes diagnosis by light microscopy. It has also been claimed that glomerulonephritis is more frequent in diabetic compared with nondiabetic patients. This has been found in neither our autopsy series (46) nor a review of world literature by Olsen and Mogensen (47). Suggested indications for renal biopsy are summarized in Table 2.

View this table:
  • View inline
  • View popup

Table 2. Indications for renal biopsy in albuminuric patients with type 2 diabetes

Control of Glycemia

Control of glycemia in type 2 diabetic patients with nephropathy represents some peculiar aspects. Why should one aim for optimal glycemic control? Today there is no longer any doubt that tight glycemic control prevents the onset or progression of diabetic nephropathy in type 2 diabetic patients (48,49⇓) as it does in type 1 diabetic patients. In the past, it had been thought that once clinically manifest nephropathy had developed, a point of no return was reached beyond which tight glycemic control failed to prevent the further decline in renal function. Nevertheless recent studies from the Steno Hospital showed that glycemic control had some, although less pronounced compared with tight BP control, effect on the rate of progression (50). The most impressive evidence for the role of hyperglycemia, so far only in type 1 diabetic patients, comes from observations on patients with isolated pancreas transplants in whom delayed reversal of glomerulosclerosis was achieved by prolonged normoglycemia (51). Furthermore, glycemic control affects survival. Wu et al. (52) found that type 2 diabetic patients with poor glycemic control in the last 6 mo before the start of dialysis had much worse survival than patients with good glycemic control, and this is also true in type 2 diabetic patients on dialysis (53).

In the United Kingdom Perspective Study UKPDS (49) no threshold was found for any of the microvascular complications above normal glucose levels (HbA1c > 6.2%). It has therefore been concluded that the lower the HbA1c value, the better. Enthusiasm has to be tempered, however, by the consideration that tight control increases the risk of hypoglycemia. Although the risk of hypoglycemia is less in type 2 diabetes, it does exist in patients with impaired renal function. Nevertheless, even there, a target value of < 7.0 HbA1c should be reached.

A cornerstone of glycemic control is lifestyle modification (54), although the efficacy of this measure diminishes as type 2 diabetes progresses. In most patients, ancillary drug treatment is necessary and the question arises: does the drug that is used for glycemic control matter and does renal function affect dosing and efficacy of the hypoglycemic agents? Table 3 summarizes some important data on currently available oral hypoglycemic agents. There is an increasing tendency in type 2 diabetic patients to aim for tight glycemic control by adopting a regime of multiple daily insulin injections (55) to achieve target HbA1c values < 7%. This is particularly true in the difficult to control type 2 diabetic with impaired renal function. Insulin treatment is obligatory when the patient has intercurrent problems such as severe infection or surgery. With the exception of gliquidone and glimepirid, most sulfonylurea compounds (or their active metabolites) accumulate in patients with reduced renal function and may then cause prolonged episodes of hypoglycemia. The insulin-sensitizing agent metformin should not be given at all to patients with reduced renal function, e.g., serum creatinine > 1.3 mg/dl, because of the risk of life-threatening lactic acidosis (56). Meformin should also be discontinued before surgery and administration of contrast media. The alpha-glucosidase inhibitor acarbose and related compounds cause gastrointestinal side effects at a high rate. They interfere with postprandial hyperglycemia; for this reason, they reduce the risk that diabetes develops in patients with impaired glucose tolerance (57). In patients with established diabetes, it has only a limited impact on HbA1c. The new glinides augment postprandial glucose-induced insulin secretion and abrogate postprandial hyperglycemic peaks. Insulin sensitisers (glitazones) stimulate the PPR-δ receptor. These drugs are fascinating on theoretical grounds, but no data on long-term safety and efficacy are available in patients with renal failure. Glitazones do not accumulate in renal failure.

View this table:
  • View inline
  • View popup

Table 3. Drugs to treat hyperglycemia in type 2 diabetes and potential problems in patients with diabetic nephropathy

Control of Dyslipidemia

Even when patients with type 2 diabetes do not have a history of coronary heart disease, the risk of cardiovascular death is higher by a factor of 4 (58). The risk becomes abysmal when diabetic patients are in ESRD or on dialysis (2,59⇓). This has led to the recommendation (60) that in type 2 diabetic patients, LDL cholesterol concentrations should be lowered to values < 100 mg/dl irrespective of the presence or absence of CHD. In these patients, because of their high coronary risk, one should consider treatment with statins as the equivalent of primary coronary prophylaxis. Apart from its effect on CHD, dyslipidemia may also contribute to the progression of diabetic nephropathy, but only limited information on this point is available.

Patients with type 2 diabetes have a complex lipid pattern (and this is even more pronounced if patients have diabetic nephropathy) with elevated triglycerides, decreased HDL concentrations, and a concentration of LDL cholesterol that is not significantly different from nondiabetic individuals. Nevertheless, there is an excess of small dense LDL particles that are highly atherogenic. In contrast to type 1 diabetes, optimal treatment of glycemia does not normalize dyslipidemia, and this is presumably explained by the fact that even in the absence of hyperglycemia, pre-diabetic patients with impaired glucose tolerance exhibit this pattern of dyslipidemia as one facet of the metabolic syndrome.

There is now clear evidence for benefit from treatment with statins. In the Heart Protection Study (61), diabetic patients with CHD benefited from treatment with simvastatin as much as nondiabetics. In the WOSCOP study (West of Scotland Coronary Prevention Study), pravastatin therapy in nondiabetic patients even led to a 30% reduction in the hazard of developing type 2 diabetes (62), but this observation has not been consistently confirmed. The beneficial effect of statins on CV events may be mediated, at least in part, through improved endothelial cell dysfunction (63). Whether statins are also effective in type 2 diabetic patients with ESRD requires further studies. Because of some unique aspects of atherogenesis in renal failure and the potential role of nonclassical risk factors, this problem is currently being investigated in a controlled trial on dialysed type 2 diabetic patients (64).

Increased triglyceride concentrations would a priori be a good indication for fibrates. Indeed, in diabetic subjects, gemfibrozil reduced the incidence of cardiovascular events by more than 20% (65) and fenofibrate also reduced progression of coronary lesions (66). Nevertheless, the use of fibrates has not become popular in renal failure patients because of the risk of rhabdomyolysis, particularly when fibrates are used that are partially eliminated by renal excretion.

Hypertension in Type 2 Diabetes

Hypertension — Pathogenesis.

Hypertension plays a major role in the onset and progression of diabetic nephropathy as well as in the development of macrovascular lesions. There has been some recent evidence that genetic predisposition to hypertension may predispose to the development of diabetic nephropathy. Strojek et al. (67) noted that BP values were significantly higher in offspring of parents with type 2 diabetes compared with those without diabetic nephropathy. Pre-diabetic individuals with impaired glucose tolerance frequently have hypertension as one facet of the metabolic syndrome. In Pima Indians such pre-diabetic hypertension has been shown to be a predictor of diabetic nephropathy (5 yrs after onset of diabetes) (68). At the time when type 2 diabetes had been diagnosed but acute hyperglycemia had been reversed, abnormal ambulatory BP values (> 130/80 mmHg) or an abnormal circadian BP profile (< 15% nighttime decrease) was noted in 80% of the patients (15). Apparently, an inappropriate decrease of nighttime BP early on is somehow related to the onset of nephropathy, as recently also shown in type 1 diabetes by Lurbe et al. (69). In type 2 diabetic patients, it is also a powerful predictor of cardiovascular death, increasing the risk by a factor of 20 (70). It is also related to the risk of progression to dialysis dependency. Even when diabetic patients are normotensive at baseline, an excessive BP increase may be observed during exercise.

Non-proteinuric type 2 diabetic patients who subsequently develop overt proteinuria and diabetic nephropathy have higher BP values (71), as shown in Table 4.

View this table:
  • View inline
  • View popup

Table 4. Hypertension preceding manifest nephropathy in type 2 diabetic patients (reference 71)a

The pulsatile BP profile in type 2 diabetes is strongly influenced by reduced aortic compliance causing higher peak systolic and lower end-diastolic pressures at any given mean arterial pressure. As a result, the BP amplitude is increased. In such patients, systolic BP is often elevated despite normal diastolic BP values (isolated systolic hypertension). In this context, it is notable that systolic BP is the strongest predictor of progression, strokes, and CV events (72). In diabetic patients with ESRD, a high pulse wave velocity as a surrogate marker for reduced vascular compliance significantly predicted mortality (73).

Although the type 2 diabetic patient is usually hypertensive before the onset of nephropathy, nephropathy aggravates the severity of hypertension. It would be beyond the scope of this article to discuss the mechanisms through which renal dysfunction affects BP: mainly sodium retention, inappropriate activity of the renin angiotensin system (RAS), sympathetic overactivity, and impaired endothelial cell-dependent vasodilatation (72). Because these pathomechanisms have consequences for the selection of antihypertensive agents, it is for instance important that at similar levels of GFR diabetic patients are consistently more hypervolemic than nondiabetic patients (74), underlining the importance of reduced dietary salt intake and diuretic treatment in the antihypertensive management of diabetic patients with nephropathy. A low sodium diet potentiates the antihypertensive and antiproteinuric effect of AT-1 receptor antagonists in type 2 diabetes (75). An average daily intake of 6 g of NaCl is recommended by the ADA (76).

The role of excessive activity of the RAS, at least of the local system in the kidney, and of the sympathetic system explains why pharmacologic blockade of the RAS and sympathetic system is so effective.

Hypertension is a potent predictor of microvascular (renal and retinal) and cardiovascular (coronary, cerebrovascular, peripheral artery disease) complications of diabetes. Coexistance of hypertension and hyperglycemia dramatically and synergistically increases the risk of these complications (for review, see reference 77). It appears that hyperglycemia “sensitizes” the vascular system to the complications of hypertension. It is beyond the scope of this review to discuss the cardiovascular benefit derived from lowering BP in type 2 diabetic patients, but this has clearly been documented in the UKPDS (78) and Hypertension Optimal Treatment (HOT) studies (79). The justification for such provocatively low target BP, the safety of which had been hotly contested in the past, is reinforced by the results of the Prospective Studies Collaboration (80) that, even in nondiabetic individuals, the lowest cardiovascular risk is seen at systolic pressures of 120 mmHg.

Prevention of the Onset of Diabetic Nephropathy

A certain consensus has been reached with respect to the recommendations for prevention and retardation of progression of diabetic nephropathy. We refer particularly to the updated Clinical Practice Recommendations of the American Diabetes Association (81).

Table 5 summarizes the relevant information with respect to prevention. A group in Kumamoto documented that intensified insulin treatment prevented onset and progression of diabetic microvascular complications, including nephropathy, in type 2 diabetic patients (48). Similarly, the UKPDS found that intensified glycemic control achieving an average HbA1c of 7% decreased the overall rate of microvascular complications (retinopathy and nephropathy) by 25% irrespective how near-normoglycemia was achieved (49).

View this table:
  • View inline
  • View popup

Table 5. Prevention of the onset of diabetic nephropathy

There is no doubt that smoking increases not only the risk of onset of type 2 diabetes; it also increases the risk of development of microalbuminuria and further progression of diabetic nephropathy in type 2 diabetic patients (82). This is true even when patients are on ACE inhibitors and have achieved adequate BP control (83). Consequently, nephrologists should not remain passive, but constantly point out the adverse effects of smoking to their patients. Behavioral therapies combined with nicotine strips, antidepressants (84), and in the future possibly nicotine vaccines (85) should be considered.

It is not yet definitely established whether antihypertensive treatment and particularly pharmacologic blockade of the RAS prevent the onset of diabetic nephropathy, although some data are very suggestive indeed (86,87⇓). This point has become largely academic, however, because according to the results of the HOPE and LIFE studies even non-microalbuminuric type 2 diabetic patients should be managed with ACE inhibitors or angiotensin receptor blockers to prevent cardiovascular events.

Although there are no controlled data, there is little doubt that obesity is a potent renal risk factor (88) and this is true in type 2 diabetes as well.

The results of the observational EURODIAB trial show that excessive protein intake is correlated to the degree of microalbuminuria (89), but there is little hard evidence for a beneficial effect of dietary intervention. In later stages of diabetic nephropathy, protein intake seems to affect CV endpoints, but paradoxically not the rate of progression (90). The ADA recommends a protein intake of 0.8 to 1.0 g/kg body weight per day for patients with type 2 diabetes with microalbuminuria and 0.8 g/kg body weight per d in individuals with overt nephropathy (76). When recommending low-protein diets, it is indispensable to guarantee adequate intake of calories (30 to 35 kcal/kg per day) to maintain good nutritional status, especially in patients with preterminal renal failure who are at risk of catabolism (91). Close follow-up of these patients is recommended to avoid malnutrition. The danger of malnutrition is illustrated by the fact that in dialysis patients low body mass index predicts poor survival (92).

Various analgesics have an adverse influence on progression, and a recent study from Sweden showed that even acetaminophen and aspirin dose-dependently increased the risk of chronic renal failure (93).

Prevention of Progression

Monitoring of type 2 diabetic patients for microalbuminuria at least once per year is recommended. Microalbuminuria in type 2 diabetic patients is not as potent a renal risk predictor as in type 1 diabetic patients, but it is certainly the best available tool to identify patients in need of intensified treatment (94). To prevent progression in microalbuminuric or proteinuric patients, it is important to adopt an integrated approach, comprising tight antihypertensive control, including pharmacologic blockade of the RAS by ACE inhibitors or angiotensin receptor blockers, intensified glycemic control, cessation of smoking, body weight reduction when appropriate (91), and dietary sodium restriction. As shown in Table 6, the loss of GFR was significantly less in type 2 diabetic patients receiving such integrated structured treatment in a diabetes clinic compared wth patients managed by private physicians (95–97⇓⇓). A recent 4-yr randomized controlled trial confirmed that changes in lifestyle can be implemented in type 2 diabetic patients with appropriate education and close follow-up (98). Early involvement of the nephrologist in such a treatment program is desirable, and there is consensus that the best management of these patients is a multidisciplinary approach.

View this table:
  • View inline
  • View popup

Table 6. The impact of intensified multifactorial intervention in patients with type 2 diabetes (reference 95)

When balancing the relative importance of these measures, it goes without saying that lowering of BP presumably to target values of at least 120/70 mmHg is the single most important measure, as recently documented by the Appropriate BP Control in Diabetes (ABCD) trial (99). Nevertheless there is also recent evidence for additional BP-independent renoprotection by angiotensin receptor blocking agents and advanced (100,101⇓) and early nephropathy of type 2 diabetes (31,102⇓). In less rigorous trials, similar renoprotection, in part BP-independent, has previously also been shown for ACE inhibitors (103,104⇓), including a study documenting benefit on renal histology (105). Attempts at achieving these BP targets must be tempered by the observation that in the IDNT trial (101) the renal risk increased progressively as BP in the orthostatic position was lower, possibly because of injury from intermittent renal underperfusion potentially explained by reduced ischemia tolerance of the diabetic kidney (106).

The discussion about the relative priorities in the selection of antihypertensive agents is largely academic, at least in the opinion of the authors. To achieve the above target BP values, we and others need an average of four to five antihypertensive agents, including ACE inhibitors or angiotensin receptor blockers, diuretics, beta-blockers, and calcium channel blockers (CCB). Particularly concerning CCB, there has been much discussion whether they are safe with respect to cardiovascular (107) and renal prognosis (108). CCB are a heterogenous group, and even different galenic preparations, e.g., of short and long acting dihydropyridines, have different effects (109). In one study, an excess frequency of myocardial infarctions was found in nephropathic diabetic patients (107), but in the ALLHAT study (110), there was no indication for excess risk in type 2 diabetes, and the SYSTEUR data even showed that the relative (percent) benefit with respect to CV events derived from CCB was greater in diabetic patients (111). Although amlodipine was shown to accelerate the loss of GFR in proteinuric patients with impaired renal function in the AASK study (108), this does not mean that CCB are generally contraindicated in proteinuric patients with renal disease (109). Amlodipine did not increase the renal risk compared with placebo in the IDNT trial (43). Ruggenenti et al. (112) had also shown that in proteinuric patients with impaired renal function, proteinuria, and loss of GFR were on average higher in patients on CCB, but this was no longer the case when patients concomitantly received ACE inhibitors and had mean arterial pressure values well below 100 mmHg. Consequently, CCB are excellent partners in the multi-drug approach to control hypertension in type 2 diabetes, but the first medication should be a drug interfering with the activated RAS.

New Therapies on the Horizon?

Although the renal risk in diabetic nephropathy can be reduced by 20 to 40% (IDNT and RENAAL), the fact remains that 70% still progress, justifying attempts to develop novel therapeutic approaches. Many such treatments work well in animals (interference with TGF-β-expression, blocking the effect of AGE, antioxidative therapy), but the clinical effects of experimental approaches are, at best, limited. Some innovative strategies have been clinically tested on small numbers of patients. As an example, the glycosaminoglycan sulodexide was given to nephropathy patients with type 1 and type 2 diabetes for 4 mo (113). Albuminuria was reduced, seemingly additive to ACE inhibition. Whether this will translate into prevention of progression remains to be seen. Clinical evidence suggests a relationship between inflammatory markers such as C-reactive protein and development of diabetic nephropathy (114), but we do not know whether antiinflammatory interventions will be effective. Exciting though these novel approaches are, they should not detract from the down-to-earth task of providing the best available treatment to diabetic patients with nephropathy. We believe that diabetic nephropathy and its progression could at least be effectively slowed down, if not prevented, in the majority of patients with type 2 diabetes once the above-mentioned standard treatments were implemented in daily clinical practice.

Conclusion

The exponentially increasing number of patients with type 2 diabetes who have a doomed prognosis requires that a state-of-the-art multidisciplinary approach is brought to bear on this problem. The best would be to prevent the development of type 2 diabetes by banning all fast food restaurants. Yet, even in patients with diabetes, it is possible to prevent diabetic nephropathy and reduce progression of established nephropathy. Excellent metabolic control and lowering of BP to very low values are the keystones of therapy. Nephrologists should be involved early in the care of diabetic patients and play a pivotal role in diagnosis, prevention, and treatment of diabetic nephropathy.

  • © 2003 American Society of Nephrology

References

  1. ↵
    Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT: The kidney in maturity onset diabetes mellitus: A clinical study of 510 patients. Kidney Int 21: 730–739, 1982
    OpenUrlCrossRefPubMed
  2. ↵
    Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795–808, 1999
    OpenUrlCrossRefPubMed
  3. ↵
    Parving HH: Diabetic nephropathy: Prevention and treatment. Kidney Int 60: 2041–2055, 2001
    OpenUrlCrossRefPubMed
  4. ↵
    Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145–1151, 2002
    OpenUrlCrossRefPubMed
  5. ↵
    Harris MJ, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 21: 518–524, 1998
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Joslin EP: Textbook of Diabetes Mellitus. Boston, Lea & Febiger, 1957
  7. ↵
    Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517–529, 2001
    OpenUrlCrossRefPubMed
  8. ↵
    Ritz E, Stefanski A: Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27: 167–194, 1996
    OpenUrlCrossRefPubMed
  9. ↵
    Brownlee M: Biochemistry and molecular biology of diabetic complications. Nature 414: 813–820, 2001
    OpenUrlCrossRefPubMed
  10. ↵
    Mogensen CE: Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 42: 263–285, 1999
    OpenUrlCrossRefPubMed
  11. ↵
    Wolf G, Thaiss F: Hyperglycaemia-pathophysiological aspects at the cellular level. Nephrol Dial Transplant 10: 1109–1112, 1995
    OpenUrlPubMed
  12. ↵
    Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic hypertrophy. Kidney Int 56: 393–405, 1999
    OpenUrlCrossRefPubMed
  13. ↵
    Nowack R, Baum E, Blum W, Ritz E: Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 20: 342–347, 1992
    OpenUrlPubMed
  14. ↵
    Wang TT, Wu XH, Zhang SL, Chan JSD: Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int 53: 312–319, 1998
    OpenUrlCrossRefPubMed
  15. ↵
    Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29: 153–163, 1997
    OpenUrlCrossRefPubMed
  16. ↵
    Keller CK, Bergis KH, Fliser D, Ritz E: Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 7: 2627–2635, 1996
    OpenUrlAbstract
  17. ↵
    Freedman BI, Tuttle AB, Spray BJ: Familial predisposition to nephropathy in African-Americans with non-insulin dependent diabetes mellitus. Am J Kidney Dis 5: 710–713, 1995
    OpenUrl
  18. ↵
    Tarnow L, Gluud C, Parving HH: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13: 1125–1130, 1998
    OpenUrlCrossRefPubMed
  19. ↵
    Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodological appraisal and systematic review. J Am Soc Nephrol 9: 1653–1663, 1998
    OpenUrlAbstract
  20. ↵
    Vradali I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, Basci A, Batram CR, van der Woude FJ, Janssen B: Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3–23. Kidney Int 62: 2176–2183, 2002
    OpenUrlCrossRefPubMed
  21. ↵
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 25 [Suppl 1]: S5–S20, 2002
    OpenUrlCrossRef
  22. ↵
    Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ: Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354: 622–625, 1999
    OpenUrlCrossRefPubMed
  23. ↵
    The DECODE Study group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617–621, 1999
    OpenUrlCrossRefPubMed
  24. ↵
    Fliser D, Rett K, Hubinger A, Ritz E: Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure. Nephrol Dial Transplant 10: 643–647, 1995
    OpenUrlPubMed
  25. ↵
    Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Pattern of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39: 1569–1576, 1996
    OpenUrlCrossRefPubMed
  26. ↵
    Tobe SW, McFarlane PA, Naimark DM: Microalbuminuria in diabetes mellitus. Can Med Ass J 167: 499–503, 2002
    OpenUrlFREE Full Text
  27. ↵
    Gerstein H, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421–426, 2001
    OpenUrlCrossRefPubMed
  28. ↵
    Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 22: 393–398, 2002
    OpenUrlCrossRefPubMed
  29. ↵
    Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, Lapage J, Nast CC: Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40: 184–188, 2002
    OpenUrlCrossRefPubMed
  30. ↵
    Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z: Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44: 874–877, 2001
    OpenUrlCrossRefPubMed
  31. ↵
    Parving HH, Lehnert H, Bröcher-Mortensen J, Gomis R, Andersen S, Arner P: The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878, 2001
    OpenUrlCrossRefPubMed
  32. ↵
    Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342–348, 1999
    OpenUrl
  33. ↵
    Gross ML, Ritz E, Schoof A, Koch A, Parkman A, Hauptmann J, Tulp O, Münter K, Orth ST, Amann K: Glomerular damage in the SHR/N-cp type 2 diabetes model — Comparison of an ACE inhibitor and endothelin receptor blocker. Diabetologia 2003, in press
  34. ↵
    Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type 2 diabetes. J Clin Invest 99: 342–348, 1997
    OpenUrlCrossRefPubMed
  35. ↵
    Steffes MW, Schmidt D, Mccrery R, Basgen JM: Glomerular cell number in normal subjects and type 1 diabetic patients. Kidney Int 59: 2104–2113, 2001
    OpenUrlCrossRefPubMed
  36. ↵
    Greive KA, Nikolic-Patzerson DJ, Guimaraes MAM, Nikolovski J, Pratt LM, Mu W, Atkins RC, Comper WD: Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol 159: 1159–1170, 2001
    OpenUrlCrossRefPubMed
  37. ↵
    Osicka TM, Houlihan CA, Chan JG, Jerums G, Comper WD: Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 49: 1579–1584, 2000
    OpenUrlAbstract
  38. ↵
    Bertani T, Gambara V, Remuzzi G: Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: A light microscopy study. Diabetologia 39: 1625–1628, 1996
    OpenUrlCrossRefPubMed
  39. ↵
    Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D: Renal pathology patterns in type 2 diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 13: 2547–2552, 1998
    OpenUrlCrossRefPubMed
  40. ↵
    Berrut G, Bouhanick B, Fabbri P, Guilloteau G, Bled F, LeJeune JJ, Fressinaud P, Marre M: Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol 48: 92–97, 1997
    OpenUrlPubMed
  41. ↵
    Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalal Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49: 476–484, 2000
    OpenUrlAbstract
  42. ↵
    Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G: Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 43: 649–655, 1994
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Hunsicker LEJ, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001
    OpenUrlCrossRefPubMed
  44. ↵
    Rodby R, Gilbert R, for the Collaborative Study Group: The presence of retinopathy is associated with poor renal and cardiovascular outcomes in type 2 diabetic nephropathy [Abstract]. J Am Soc Nephrol 13: 644A, 2002
    OpenUrl
  45. ↵
    Parving HH, Gall MA, Skott J, Jorgensen HE, Lokegaard H, Jorgensen F: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: 758–762, 1992
    OpenUrlCrossRefPubMed
  46. ↵
    Waldherr R, Ilkenhans C, Ritz E: How frequent is glomerulonephritis in diabetes mellitus type II ? Clin Nephrol 37: 271–273, 1992
    OpenUrlPubMed
  47. ↵
    Olsen S, Mogensen CE: How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 39: 1638–1645, 1996
    OpenUrlCrossRefPubMed
  48. ↵
    Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized propsective 6-year study. Diab Res Clin Prac 28: 103–117, 1995
  49. ↵
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998
    OpenUrlCrossRefPubMed
  50. ↵
    Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702–709, 2001
    OpenUrlCrossRefPubMed
  51. ↵
    Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69–75, 1998
    OpenUrlCrossRefPubMed
  52. ↵
    Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, Fan Chian CY, Hunag CC, Leu ML: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12: 2105–2110, 1997
    OpenUrlCrossRefPubMed
  53. ↵
    Morioka T, Emoto M, Tabata T, Shoij t, Thara H, Kishimoto H: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909–913, 2001
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347: 1342–1349, 2002
    OpenUrlCrossRefPubMed
  55. ↵
    Herbst KL, Hirsch IB: Insulin strategies for primary care providers. Clin Diab 20: 11–17, 2002
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: An update. Ann Intern Med 137: 25–33, 2002
    OpenUrlCrossRefPubMed
  57. ↵
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laaksch M: Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359: 2072–2077, 2002
    OpenUrlCrossRefPubMed
  58. ↵
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234, 1998
    OpenUrlCrossRefPubMed
  59. ↵
    Baigent C, Burburry K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147–152, 2000
    OpenUrlCrossRefPubMed
  60. ↵
    American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diab Care 25 [Suppl 1]: S74–S77, 2002
    OpenUrlCrossRef
  61. ↵
    Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering simvastatin in 20,536 high risk individuals: A randomized placebo-controlled trial. Lancet 360: 7–22, 2002
    OpenUrlCrossRefPubMed
  62. ↵
    Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Mafarlane PW, McKillop JH, Packard CJ, Shepherd J, Gawa A: Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357–362, 2001
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation 106: 1211–1218, 2002
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Wanner C, Krane V, Ruf G, Marz W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetes on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222–S226, 1999
    OpenUrlPubMed
  65. ↵
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410–418, 1999
    OpenUrlCrossRefPubMed
  66. ↵
    Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905–910, 2001
    OpenUrlCrossRefPubMed
  67. ↵
    Strojek K, Grzeszczak W, Morawin E, Adamski M, Lacka B, Rudzi H, Schmidt S, Keller C, Ritz E: Nephropathy of type II diabetes: Evidence for heriditary factors ? Kidney Int 51: 1602–1607, 1997
    OpenUrlCrossRefPubMed
  68. ↵
    Nelson RG, Pettin DJ, Baird HR, Charles MA, Liu QZ, Bennett PH, Knowler WC: Prediabetic blood pressure predicts urinary albumin secretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 36: 998–1001, 1993
    OpenUrlCrossRefPubMed
  69. ↵
    Lurbe L, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Battle D: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347: 797–805, 2002
    OpenUrlCrossRefPubMed
  70. ↵
    Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi t, Uchika K: Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabets 47: 1501–1506, 1998
    OpenUrl
  71. ↵
    Hasslacher C, Wolfrum M, Stech G, Wahl P, Ritz E: Diabetic nephropathy in type 2 diabetes: Effect of metabolic control and blood pressure on its development and course. Dtsch Med Wschr 18: 1445–1449, 1987
    OpenUrl
  72. ↵
    Adamczak M, Zeier M, Dikow R, Ritz E: Kidney and hypertension. Kidney Int Suppl 80: 62–67, 2002
  73. ↵
    Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12: 2117–2124, 2001
    OpenUrlAbstract/FREE Full Text
  74. ↵
    Ritz E, Fliser D, Nowicki M: Hypertension and vascular disease as complications of diabetes. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed, edited by Laragh JH, Brenner BM, New York, Raven Press, 1995, pp 2321–2334
  75. ↵
    Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley D, Cooper ME, Jerums G: A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diab Care 25: 663–671, 2002
    OpenUrlAbstract/FREE Full Text
  76. ↵
    American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diab Care 25 [Suppl 1]: S50–S60, 2002
    OpenUrlCrossRef
  77. ↵
    American Diabetes Association: Treatment of hypertension in adults with diabetes. Diab Care 25 [Suppl 1]: S71–S73, 2002
    OpenUrlCrossRef
  78. ↵
    Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Brit Med J 321: 412–419, 2000
    OpenUrlAbstract/FREE Full Text
  79. ↵
    Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762, 1998
    OpenUrlCrossRefPubMed
  80. ↵
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective stdueis. Lancet 360: 1903–1913, 2002
    OpenUrlCrossRefPubMed
  81. ↵
    Summary of Revisions for the 2003 Clinical Practice Recommendations. Diabetes Care 26: S3, 2003
    OpenUrl
  82. ↵
    Orth SR, Ritz E, Schrier RW: The renal risks of smoking. Kdiney Int 51: 1669–1677, 1997
    OpenUrl
  83. ↵
    Chuahirun T, Wesson DE: Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis 39: 376–382, 2002
    OpenUrlPubMed
  84. ↵
    Orth SR, Ogata H, Ritz E: Smoking and the kidney. Nephrol Dial Transplant 15: 1509–1511, 2000
    OpenUrlCrossRefPubMed
  85. ↵
    Pentel P, Malin D: A vaccine for nicotine dependence: Targeting the drug rather than the brain. Respiration 69: 193–197, 2002
    OpenUrlCrossRefPubMed
  86. ↵
    HOPE Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259, 2000
    OpenUrlCrossRefPubMed
  87. ↵
    Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086–1097, 2002
    OpenUrlCrossRefPubMed
  88. ↵
    Praga M: Obesity — A neglected culprit in renal disease. Nephrol Dial Transplant 17: 1157–1159, 2002
    OpenUrlCrossRefPubMed
  89. ↵
    Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, Gries FA, Keen H: Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 40: 1219–1226, 1997
    OpenUrlCrossRefPubMed
  90. ↵
    Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62: 220–228, 2002
    OpenUrlCrossRefPubMed
  91. ↵
    Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, Casciani CU: Severe dietary protein restriction in overt diabetic nephropathy: Benefits or risks? J Ren Nutr 12: 96–101, 2002
    OpenUrlCrossRefPubMed
  92. ↵
    Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PH, Young EW: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62: 2238–2245, 2002
    OpenUrlCrossRefPubMed
  93. ↵
    Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O: Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345: 1801–1808, 2001
    OpenUrlCrossRefPubMed
  94. ↵
    Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G: The nephropathy of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 9: 2336–2343, 1998
    OpenUrlAbstract
  95. ↵
    Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353: 617–622, 1999
    OpenUrlCrossRefPubMed
  96. ↵
    Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M: Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus — A randomized prospective study. Diabet Med 19: 385–392, 2002
    OpenUrlCrossRefPubMed
  97. ↵
    Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393, 2003
    OpenUrlCrossRefPubMed
  98. ↵
    Trento M, Passera P, Bajardi M, Tomalino M, Grassi G, Borgo E, Donnola C, Cavallo F, Bodnonio P, Porta M: Lifestyle intervention by group care prevents deterioration of type II diabetes: A 4-year randomized controlled clinical trial. Diabetologia 45: 1231–1239, 2002
    OpenUrlCrossRefPubMed
  99. ↵
    Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086–1097, 2002
  100. ↵
    Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001
    OpenUrlCrossRefPubMed
  101. ↵
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001
  102. ↵
    Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106: 672–678, 2002
    OpenUrlAbstract/FREE Full Text
  103. ↵
    Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 128: 982–988, 1998
    OpenUrlCrossRefPubMed
  104. ↵
    Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20: 1576–1581, 1997
    OpenUrlAbstract/FREE Full Text
  105. ↵
    Cordonnier DJ, Pinels N, Barro C, Maynard C, Zaoui P, Halimi S, Hurauldt de Ligny B, Reznic Y, Simon D, Bilous RW: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 10: 1253–1263, 1999
    OpenUrlAbstract/FREE Full Text
  106. ↵
    Melin J, Hellberg O, Akyurek LM, Kallskog O, Larsson E, Fellstrom BC: Ischemia causes rapidly progressive nephropathy in the diabetic rat. Kidney Int 52: 985–991, 1997
    OpenUrlCrossRefPubMed
  107. ↵
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645–652, 1998
    OpenUrlCrossRefPubMed
  108. ↵
    Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JH, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Le J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr. Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. JAMA 285: 2719–2728, 2001
    OpenUrlCrossRefPubMed
  109. ↵
    Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 35: 646–661, 2000
    OpenUrl
  110. ↵
    The ALLHAT officers: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attach trial (ALLHAT). JAMA 288: 3039–3042, 2002
    OpenUrlCrossRefPubMed
  111. ↵
    Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340: 677–684, 1999
    OpenUrlCrossRefPubMed
  112. ↵
    Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 9: 2096–2101, 1998
    OpenUrlAbstract
  113. ↵
    Gambaro G, Kinalska I, Oksa A, Pont’uch P, Hertlová M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicová J, Skrha J, Taton J, Grzesczak W, Crepaldid G: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 13: 1615–1625, 2002
    OpenUrlAbstract/FREE Full Text
  114. ↵
    Festa A, Dágostino R, Howard G, Mykkanen L, Tracy RP, Haffne SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The insulin resistance atherosclerosis study. Kidney Int 58: 1703–1710, 2000
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 14 (5)
Journal of the American Society of Nephrology
Vol. 14, Issue 5
1 May 2003
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management
Gunter Wolf, Eberhard Ritz
JASN May 2003, 14 (5) 1396-1405; DOI: 10.1097/01.ASN.0000065639.19190.CF

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management
Gunter Wolf, Eberhard Ritz
JASN May 2003, 14 (5) 1396-1405; DOI: 10.1097/01.ASN.0000065639.19190.CF
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Conclusion
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Polycystic Kidney Disease
  • Genotype–Phenotype Correlations in Autosomal Dominant and Autosomal Recessive Polycystic Kidney Disease
  • Role of Primary Cilia in the Pathogenesis of Polycystic Kidney Disease
Show more Frontiers in Nephrology

Cited By...

  • Risk Factors for Developing Diabetic Foot Ulcer with Nephropathy, Diabetic Kidney Disease and Renal Failure Statistical Analysis of 10,680 Patients Cohort
  • Role of the potassium channel KCa3.1 in diabetic nephropathy
  • Diabetic Nephropathy for the Primary Care Provider: New Understandings on Early Detection and Treatment
  • Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
  • Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis: A 7-year observational study
  • Diet Therapy With Diacylglycerol Oil Delays the Progression of Renal Failure in Type 2 Diabetic Patients With Nephropathy
  • Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
  • Chronic Angiotensin II Receptor Blockade Reduces (Intra)Renal Vascular Resistance in Patients with Type 2 Diabetes
  • Proteomic analysis for the assessment of diabetic renal damage in humans
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire